STENOCARE A/S (“Stenocare”) delivered products to its 5 markets during Q4 2022 corresponding to net sales of 2.8 mDKK and is on track for its sales expectations for 2023 in the range of 15-20 mDKK
Investor Update: The first shipment of Stenocare medical cannabis oil products has arrived in Norway and the products are ready for patients.
Investor Update: Today, the new STENOCARE CBD medical cannabis oil product is available in Denmark. The first shipment has arrived, and sales of the product can begin.
Stenocare accesses the Norwegian market. Stenocare has signed a distribution agreement with the leading distributor and pharmacy chain.
STENOCARE and Emerald have been accepted by Swedish health authorities to offer patients’ treatment with medical cannabis oil
STENOCARE – First day of trading on NASDAQ FIRST NORTH GROWTH MARKET DENMARK will be 18 May 2020
STENOCARE signs agreement with new prominent supplier, PANAXIA and announces imminent product approval application filing
STENOCARE: Notification of changes in major shareholding and increased holding of own shares.
STENOCARE and OWC Pharmaceutical Research Corp. to enter partnership to develop advanced medical cannabis products
STENOCARE to establish the world’s first hybrid, in-door cultivation facility for production of premium medical cannabis at scale
STENOCARE receives new information from CannTrust that causes immediate quarantine on sales of products from current inventory
STENOCARE products are being used in clinical trials at Rigshospitalet Multiple Sclerosis Center
STENOCARE A/S on track with the planned offering of Medical Cannabis Capsules to offer Danish patients more choice in their treatment